C
와이바이오로직스
338840KOSDAQ40.8 / 100
Reference Date: 2026-09-08
Financial Score9.0 / 40
News Sentiment18.8 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Declined 9.9% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
WaiBioLogics is a biopharmaceutical company developing advanced antibody-based therapies, including immune checkpoint inhibitors, ADCs, and bispecific antibodies, leveraging its proprietary discovery platform. Key pipelines include YBL-006, AR166, AR169, and AR170, with revenue generated through technology licensing and contract research services.
Number of Employees
58people
Average Salary
60.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
5.21Industry Average 1.200.0Point
4.3x industry avg (risky)
ROE
-186.97Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
105.13Industry Average 100.002.0Point
Higher than industry avg (caution)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲8.1% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲3.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -111.6% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75
- Positive와이바이오로직스, 우리사주조합 장내 주식 매입
와이바이오로직스의 우리사주조합 장내 주식 매입 완료로 직원 동기 부여 강화 및 기업 가치 제고 노력이 지속되고 있다.
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 8,990Won52-week high 35,60052-week low 7,520
1-month return1.0Point
1m -9.92% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral의결권대리행사권유참고서류2026-09-04
- Neutral주주총회소집공고2026-09-04
- Neutral파생상품거래손실발생2026-08-14
- Neutral주주총회소집결의 (임시주주총회)2026-08-14
- Neutral주주명부폐쇄기간또는기준일설정2026-08-14